Pain Therapeutics Company Profile (NASDAQ:PTIE)

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics logoPain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PTIE
  • CUSIP: 69562K10
  • Web: www.paintrials.com
Capitalization:
  • Market Cap: $27.48 million
  • Outstanding Shares: 6,591,000
Average Prices:
  • 50 Day Moving Avg: $2.11
  • 200 Day Moving Avg: $1.02
  • 52 Week Range: $0.51 - $4.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.35
  • P/E Growth: 0.04
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.54 per share
  • Price / Book: 1.64
Profitability:
  • EBIDTA: ($11,830,000.00)
  • Return on Equity: -68.80%
  • Return on Assets: -62.42%
Debt:
  • Current Ratio: 10.29%
  • Quick Ratio: 10.29%
Misc:
  • Average Volume: 1.14 million shs.
  • Beta: 2.13
  • Short Ratio: 1.13
 

Frequently Asked Questions for Pain Therapeutics (NASDAQ:PTIE)

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Pain Therapeutics shares reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics, Inc. (NASDAQ:PTIE) issued its quarterly earnings data on Tuesday, April, 25th. The company reported ($0.42) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.42). View Pain Therapeutics' Earnings History.

When will Pain Therapeutics make its next earnings announcement?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 17th 2017. View Earnings Estimates for Pain Therapeutics.

Where is Pain Therapeutics' stock going? Where will Pain Therapeutics' stock price be in 2017?

1 brokers have issued 12 month price targets for Pain Therapeutics' shares. Their forecasts range from $17.50 to $17.50. On average, they anticipate Pain Therapeutics' share price to reach $17.50 in the next year. View Analyst Ratings for Pain Therapeutics.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:

  • Remi Barbier, Chairman of the Board, President, Chief Executive Officer
  • Nadav Friedmann, Chief Medical and Operating Officer, Director
  • Michael Marsman Pharm.D., Senior Vice President - Regulatory Affairs
  • Robert Z. Gussin Ph.D., Independent Director
  • Michael J. O' Donnell Esq., Independent Director
  • Saira Ramasastry, Independent Director
  • Sanford R. Robertson, Independent Director
  • Patrick J. Scannon M.D., Ph.D., Independent Director

Who owns Pain Therapeutics stock?

Pain Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Eagle Investment Management LLC (14.43%), Vanguard Group Inc. (3.50%), Renaissance Technologies LLC (1.39%), Geode Capital Management LLC (0.44%), Gabelli Funds LLC (0.38%) and Bank of New York Mellon Corp (0.38%). View Institutional Ownership Trends for Pain Therapeutics.

Who sold Pain Therapeutics stock? Who is selling Pain Therapeutics stock?

Pain Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Pain Therapeutics.

Who bought Pain Therapeutics stock? Who is buying Pain Therapeutics stock?

Pain Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Geode Capital Management LLC. View Insider Buying and Selling for Pain Therapeutics.

How do I buy Pain Therapeutics stock?

Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of Pain Therapeutics stock can currently be purchased for approximately $4.17.


MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $17.50 (319.66% upside)

Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/13/2016GabelliDowngradeBuy -> Hold$17.50N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Pain Therapeutics (NASDAQ:PTIE)
Earnings by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Earnings History by Quarter for Pain Therapeutics (NASDAQ:PTIE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/17/2017        
4/25/2017Q1 2017($0.42)($0.42)ViewN/AView Earnings Details
10/20/2016Q316($0.63)($0.56)ViewN/AView Earnings Details
7/19/2016Q216($0.98)($0.49)ViewN/AView Earnings Details
5/5/2016Q1($0.70)($0.91)ViewN/AView Earnings Details
10/30/2014Q314($0.56)$89.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.49)ViewN/AView Earnings Details
5/6/2014Q1 14($0.42)($0.56)$1.96 millionViewN/AView Earnings Details
2/4/2014Q413($0.07)$5.04$2.00 million$35.24 millionViewN/AView Earnings Details
10/31/2013Q313($0.07)($0.14)$2.00 million$1.96 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.07)($0.07)$2.80 million$1.96 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.14)($0.56)$2.79 million$2.47 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)
Current Year EPS Consensus Estimate: $1.29 EPS
Next Year EPS Consensus Estimate: $-3.09 EPS

Dividends

Dividend History by Quarter for Pain Therapeutics (NASDAQ:PTIE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$5.2512/13/201212/17/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pain Therapeutics (NASDAQ:PTIE)
Insider Ownership Percentage: 32.40%
Institutional Ownership Percentage: 44.34%
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Institutional Ownership by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pain Therapeutics (NASDAQ:PTIE)
Latest Headlines for Pain Therapeutics (NASDAQ:PTIE)
Source:
DateHeadline
businesswire.com logoAntibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346
www.businesswire.com - May 12 at 8:10 AM
globenewswire.com logoPain Therapeutics Announces Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - May 10 at 11:24 AM
streetinsider.com logoPain Therapeutics (PTIE) 7-for-1 Reverse Stock Split Effective 05/09 - StreetInsider.com
www.streetinsider.com - May 10 at 11:24 AM
finance.yahoo.com logoPain Therapeutics Announces Reverse Stock Split
finance.yahoo.com - May 8 at 11:55 AM
americanbankingnews.com logoPain Therapeutics (PTIE) Receives Daily News Impact Score of 0.17
www.americanbankingnews.com - May 4 at 9:24 PM
americanbankingnews.com logoPain Therapeutics (PTIE) Getting Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 29 at 6:10 PM
americanbankingnews.com logoPain Therapeutics, Inc. (PTIE) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 28 at 10:17 AM
americanbankingnews.com logoPositive News Coverage Very Likely to Affect Pain Therapeutics (PTIE) Stock Price
www.americanbankingnews.com - April 26 at 9:40 PM
americanbankingnews.com logoPain Therapeutics, Inc. (PTIE) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - April 26 at 4:16 PM
finance.yahoo.com logoPain Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - April 25 at 6:29 PM
finance.yahoo.com logoPain Therapeutics reports 1Q loss
finance.yahoo.com - April 25 at 6:29 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Affect Pain Therapeutics (PTIE) Stock Price
www.americanbankingnews.com - April 23 at 9:55 AM
americanbankingnews.com logoPain Therapeutics (PTIE) Earning Somewhat Critical News Coverage, Report Shows
www.americanbankingnews.com - April 18 at 7:59 PM
americanbankingnews.com logoPain Therapeutics (PTIE) Getting Somewhat Negative News Coverage, Report Shows
www.americanbankingnews.com - April 15 at 2:13 PM
americanbankingnews.com logoShort Interest in Pain Therapeutics, Inc. (PTIE) Grows By 122.3%
www.americanbankingnews.com - April 15 at 7:04 AM
americanbankingnews.com logoPain Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($0.40) Per Share (PTIE)
www.americanbankingnews.com - March 27 at 9:39 AM
americanbankingnews.com logoGabelli Comments on Pain Therapeutics, Inc.'s FY2021 Earnings (PTIE)
www.americanbankingnews.com - March 24 at 2:28 PM
streetinsider.com logoPain Therapeutics (PTIE) Surges Following Positive REMOXY Regulatory Guidance
www.streetinsider.com - March 21 at 7:09 PM
nasdaq.com logoPTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes
www.nasdaq.com - March 21 at 10:46 AM
investopedia.com logoPain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE, EGLT)
www.investopedia.com - March 21 at 10:46 AM
biz.yahoo.com logoPAIN THERAPEUTICS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 10:46 AM
seekingalpha.com logoPain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket
seekingalpha.com - March 21 at 7:43 AM
feeds.benzinga.com logoPain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER
feeds.benzinga.com - March 20 at 7:54 PM
finance.yahoo.com logoPAIN THERAPEUTICS INC Financials
finance.yahoo.com - March 11 at 7:10 PM
biz.yahoo.com logoPAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 7:15 PM
seekingalpha.com logoPain Therapeutics finance chief bids adieu
seekingalpha.com - February 18 at 6:29 PM
us.rd.yahoo.com logoPain Therapeutics Reports 2016 Financial Results
us.rd.yahoo.com - February 18 at 6:29 PM
biz.yahoo.com logoPAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
us.rd.yahoo.com - February 18 at 6:29 PM
us.rd.yahoo.com logo9:09 am Pain Therapeutics discloses that it and the FDA reached an agreement on a roadmap to resubmit the New Drug Application for REMOXY ER
us.rd.yahoo.com - February 18 at 6:29 PM
globenewswire.com logoPain Therapeutics Reports 2016 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 17 at 8:05 PM
seekingalpha.com logoPain Therapeutics net loss improves in Q4
seekingalpha.com - February 17 at 10:01 AM
fool.com logoPain Therapeutics PTIE
www.fool.com - January 29 at 12:31 AM
globenewswire.com logoPain Therapeutics to Discuss REMOXY® ER with FDA - GlobeNewswire (press release)
globenewswire.com - December 20 at 1:59 PM

Social

Chart

Pain Therapeutics (PTIE) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff